HIMS is a major player in the compounded semaglutide space. It spent hundreds of millions to promote their offering in the weight loss space, making use of the shortage in Ozempic and other GLP1s in recent months. The company's offerings include semaglutide-based injections, marketed as containing the same active ingredient as popular brands like Ozempic and Wegovy, along with other weight loss options.
But there is now a big problem, the FDA has just announced the shortages are over.
What does this mean for HIMS? Only time will tell but I don’t think this rally can go on a whole lot longer. Whilst we have a lovely rounded bottom pattern I suspect some downwards pressure on the stock so I’m leaning short to mid term bearish, unless the upcoming earnings deliver blockbuster numbers and my idea will be invalidated.
The valuation is too stretched and I don’t think this news will justify the extreme optimism in this high growth stock. So I suspect a drop into the gap fill soon.
Not financial advice, do what’s best for you.
But there is now a big problem, the FDA has just announced the shortages are over.
What does this mean for HIMS? Only time will tell but I don’t think this rally can go on a whole lot longer. Whilst we have a lovely rounded bottom pattern I suspect some downwards pressure on the stock so I’m leaning short to mid term bearish, unless the upcoming earnings deliver blockbuster numbers and my idea will be invalidated.
The valuation is too stretched and I don’t think this news will justify the extreme optimism in this high growth stock. So I suspect a drop into the gap fill soon.
Not financial advice, do what’s best for you.
交易進行
Entered short at $30 , a key psychological level. Trade already up 20%, stop loss at $31
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。